IP Library Granted Patent US 11,534,394
Granted Patent B2
US 11,534,394 · App. 16/734,367 · Granted Dec 27, 2022

Pharmaceutical composition containing botulinum neurotoxin

Inventors: Paul Webb (Wrexham, GB); Mary White (Wrexham, GB); Julie Partington (Wrexham, GB)
Assignee: IPSEN BIOPHARM LIMITED
A61K9/0019A61K9/19A61K38/4886A61K38/4893A61K47/02A61K47/183A61K47/22A61K47/26A61P17/00C12Y304/24069Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,534,394
App. No.
16/734,367
Granted
Dec 27, 2022
Kind
B2
Abstract

Method for treating a disease, condition, or syndrome in a subject comprising administering, to a subject in need thereof, a solid or liquid pharmaceutical composition comprising: (a) a high purity botulinum neurotoxin or a complex comprising botulinum neurotoxin, wherein the botulinum neurotoxin is of type A, B, C, D, E, F or G; and (b) a surfactant; wherein the composition does not comprise albumin or a polysaccharide.

Claims (11)

1. A method for treating wrinkles comprising administering to a subject in need thereof a composition comprising:

(a) a high purity botulinum neurotoxin or a complex comprising botulinum neurotoxin, wherein the botulinum neurotoxin is of type A, B, C, D, E, F or G; and

(b) a surfactant;

wherein the composition does not comprise albumin or a polysaccharide.

2. The method of claim 1 , wherein the composition further comprises sodium chloride.

3. The method of claim 1 , wherein the composition further comprises a buffer capable of maintaining an aqueous solution at a pH between 5.5 and 7.5.

4. The method of claim 1 , wherein the composition further comprises a disaccharide.

5. The method of claim 1 , wherein the botulinum neurotoxin is a botulinum neurotoxin type A.

6. The method of claim 1 , wherein the botulinum neurotoxin complex or high purity botulinum neurotoxin is administered in a therapeutically efficient quantity.

7. The method of claim 1 , for treating glabellar frown lines.

8. The method of claim 1 , for treating facial wrinkles.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2020
From: WEBB, PAUL; WHITE, MARY; PARTINGTON, JULIE
To: IPSEN LIMITED
Reel/Frame 051417/0396 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2020
From: IPSEN DEVELOPMENTS LIMITED
To: IPSEN BIOPHARM LIMITED
Reel/Frame 051417/0404 →
CHANGE OF NAME Recorded Jan 5, 2020
From: IPSEN LIMITED
To: IPSEN DEVELOPMENTS LIMITED
Reel/Frame 051540/0684 →
Priority Claims (1)
GB 0415491 · Jul 12, 2004 · national
Continuity (4)
Continuation 15671727 · Aug 8, 2017
Continuation 14810975 · Jul 28, 2015
Continuation 11632156
Related Publication 20200164050A1 · May 28, 2020